STUDresearch · Non-peptide

Cabergoline

Also known as

Dostinex (Pfizer brand) · caber (forum shorthand) · Cabaser (some Parkinson’s-market branding) · Cabgolin (Sun Pharma generic branding, discussed) · Apo-Cabergoline / ACT Cabergoline (Canadian generics) · Cabergoline tablets 0.5 mg (scored)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗

Non-peptide Niche talk Systemic Oral Hormone modulators

Oral dopamine agonist that lowers prolactin, with effects beyond the pituitary including dizziness, sleepiness and impulse-control changes.

What people say Cabergoline is a long-acting dopamine agonist used to lower prolactin. People discuss prolactinoma treatment, libido changes and AAS-related hormone concerns; it is not an estrogen blocker or a general-purpose libido booster. Doses people talk about

AAS forum example · off-label0.25 mg twice weekly

Oral-tablet discussion: a copied pattern, not a recommendation or an automatic accompaniment to other hormones.

Clinical weekly totals discussed0.5–2 mg per week

Oral hyperprolactinemia/prolactinoma notes; this is a weekly total, not a per-dose instruction.

Prescription treatment and AAS forum use are different settings. A copied label amount does not establish safe unsupervised use.

Half-life & effect duration

Half-life in the body: Healthy volunteersAbout 63–68 hours
High-prolactin patientsAbout 79–115 hours
Felt duration people report: One patient accountSide effects began within a day and lasted 2–3 days
Other accountsMore alertness afterward, or early next-day lightheadedness that later stopped

Timing context & sources

How it may feel Some people report improved sexual symptoms; others describe nausea, headache, lightheadedness, fatigue or a flat mood. The reason for treatment and other medicines matter.

Cycles people discuss Clinical treatment can last months or years with monitoring. Bodybuilding discussions tie use to another drug cycle, but that is not an established Cabergoline cycle or a substitute for identifying the underlying problem. Timing Weekly rather than daily schedules dominate the discussion. Some people describe taking it with food because of nausea; the long elimination time does not guarantee that side effects end overnight. Stacks 19-nor AAS adjacency: Most-discussed pairing is with nandrolone (Deca/NPP) or trenbolone when users attribute lactation-type sides, sexual dysfunction, or “prolactin gyno” to those compounds. Caber is treated as a side-management tool, not an anabolic. Watch for Orthostatic hypotension: Standing BP drop, lightheadedness, syncope risk — especially early treatment or after dose hikes; initial single doses ≥1 mg raise orthostatic concern in product monographs. Greater risk with concurrent BP-lowering drugs. Rise slowly from sitting/lying.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

The Dostinex information lists 63–68 hours in healthy volunteers and 79–115 hours in patients with high prolactin.

Those estimates used different assays. They are not a single personal range or a clock for libido, alertness or prolactin recovery.

Healthy-volunteer estimates used radioimmunoassay; patient estimates used HPLC. Rat pituitary radioactivity and prolonged human prolactin suppression are separate endpoints.

Dostinex product information: distinct elimination estimates (opens in a new tab)Section 5.2: urinary-excretion estimates and RIA/HPLC methods; section 5.1 separates pituitary radioactivity and prolactin suppression.Official summary, not an individual prediction or a disease-only comparison between assays.

Felt duration people report

One patient describes side effects beginning within a day and lasting two to three days. Others describe more alertness afterward or early next-day lightheadedness that later stopped.

These are patient experiences, not a predictable bodybuilding or libido benefit window.

The first poster reports migraines, other health conditions and stress, with a later follow-up saying side effects resolved during longer treatment. Different diagnoses and coexisting symptoms limit comparison.

Cabergoline: early side effects and later follow-up (opens in a new tab)sensual_shakespeare reply to Jenn_Hdez: within 24 hours, lasting two to three days; later reply reports over a year without side effects.Migraines, comorbidities and stress are disclosed. Later tolerance is not proof of a universal adaptation period.
Cabergoline: alertness and lightheadedness experiences (opens in a new tab)flailingbird: alertness in days after tablets. adenoyourosis: early next-day lightheadedness that later ceased.Individual patient stories; symptom benefit is not evidence for unsupervised AAS use.

What people say 10

AAS 19-nor side lore: Forums report relief of lactation-type discharge, “prolactin gyno” narrative, nipple sensitivity, and some sexual dysfunction when users believe prolactin is elevated on Deca/tren. Confounders (estrogen, progestin activity, sleep, other drugs) are heavily debated. forum
Libido (mixed, context-bound): Some users report better drive once high prolactin is lowered; others report libido crash, anhedonia, or dull mood if prolactin is driven too low or if sides dominate. forum
Prolactin normalization (dose-response trial): In a 4-week placebo-controlled hyperprolactinemia study, prolactin normalized in ~29% / 76% / 74% / 95% of patients on 0.125 / 0.5 / 0.75 / 1.0 mg twice weekly respectively — clear dose relationship. trial
Vs bromocriptine head-to-head: Landmark multi-center work (Webster et al., NEJM 1994-line data) — cabergoline normalized prolactin in ~77% vs ~59% on bromocriptine; menses restoration and galactorrhea resolution also favored cabergoline; side effects fewer/shorter. trial
Sexual function when prolactin is high: Comparative clinical work reported cabergoline superior to bromocriptine for sexual desire in both sexes; men also improved erectile/orgasmic scores when hyperprolactinemia was treated. trial
Healthy-volunteer prolactin / sexual signals: Older experimental work lowering prolactin with cabergoline in men reported improvements across sexual drive/function metrics when prolactin was manipulated — context-dependent, not a free libido drug. trial
Macroprolactinoma / tumor talk: Used under specialists for prolactin cut and possible adenoma shrinkage; visual-field improvement discussed when compression was prolactinoma-driven. trial
Galactorrhea / ovulatory cycles: Clinical series: inappropriate lactation often clears; amenorrhea/oligomenorrhea may reverse if prolactin was the driver. trial
Dosing convenience: Twice-weekly (sometimes once-weekly) oral schedule vs multi-daily older agonists is a major practical reason clinicians and users prefer it over bromocriptine. trial
Bromocriptine-intolerant / resistant cases: Large retrospective hyperprolactinemia series reported high rates of prolactin normalization after switch to cabergoline, including many prior bromocriptine failures. trial

Doses people talk about 17

Bodybuilding / AAS forum common start: Most-repeated community template is ~0.25 mg twice weekly (often Mon/Thu) if prolactin-type symptoms appear on 19-nors — mirroring the clinical start, not inventing a separate “blast” dose. forum
Lower / micro patterns: Some write-ups cite ~0.25–0.5 mg total per week split into two doses for milder support; others use 0.25 mg E3D (every third day) as a personal schedule variant — less standardized than twice-weekly. forum
Split-tablet math: Standard 0.5 mg scored tabs → 0.25 mg halves; quartering to ~0.125 mg appears in low-start talk but invites uneven dose. Pill cutters help; still imprecise vs pharmacy strengths. forum
Uncertainty / product risk: Gray-market “caber” tablets may be under/over-potent or counterfeit; pharmacy-sourced product ≠ research-chem identity. Tiny absolute doses magnify percent error from bad splits or fake tabs. forum
BB escalation talk: If symptoms persist, some logs step toward ~0.5 mg twice weekly; “up to 1 mg twice weekly” is sometimes repeated as an upper-safe-sounding ceiling — that matches labeled max, not a free pass. Faster than monthly titration is higher-risk talk. forum
Dose-response (4-week trial arms): 0.125 / 0.5 / 0.75 / 1.0 mg twice weekly produced stepwise prolactin normalization rates (~29–95%) — supports “start low, verify labs” culture. trial
Clinical maintenance band: Many prolactinoma/hyperprolactinemia patients land around ~0.5–2 mg/week total; some series reduced dose once control was achieved (e.g. median start ~1 mg/week, maintenance often lower). trial
Higher specialist bands: Resistant macroprolactinoma or non-standard endocrine uses (e.g. some Cushing’s literature) discuss weekly totals well above the hyperprolactinemia average (examples in literature include multi-mg/week protocols) — specialist territory, not forum default. trial
Once-weekly / every-10–14-day clinical taper lore: Because of long action, some maintenance patients in endocrine practice hold normoprolactinemia on 0.5 mg every 10–14 days after long control — disease-management taper, not a cycle trick. trial
With food: Can be taken with or without food; patient materials and forums often prefer with food to reduce nausea. Volunteer PK: food did not alter cabergoline kinetics. trial
Not daily by default: Once- or twice-weekly endocrine schedules appear in product information. They are clinical schedules, not instructions calculated from half-life; more frequent administration can change exposure. trial
Framing: Label, trial, and community-discussed ranges only — not medical advice, not AAS protocols, not a recommendation to self-medicate. forum
US labeled start (hyperprolactinemia): 0.25 mg orally twice weekly (half of a 0.5 mg scored tablet). trial
US titration rule: Increase by 0.25 mg twice weekly at intervals of no less than 4 weeks, guided by serum prolactin; maximum recommended labeled dose 1 mg twice weekly (2 mg/week total). trial
EU / multi-region label style: Often starts ~0.5 mg per week in one or two doses (e.g. Monday/Thursday); raise by ~0.5 mg/week at monthly intervals; usual therapeutic band ~1 mg/week; common range ~0.25–2 mg/week; doses up to ~4.5 mg/week have been used in hyperprolactinemic patients under care. trial
Lactation-prevention (labeled in some regions): 1 mg as a single dose (two 0.5 mg tablets) discussed for prevention of puerperal lactation. trial
Established-lactation suppression (some labels): 0.25 mg every 12 hours for two days (1 mg total) — framed as better tolerated than a single 1 mg bolus in that setting. trial

How it may feel 8

Weeks 2–8 (symptom window): AAS-forum “did caber fix Deca dick / lactation?” judgment is often made over a few weeks of consistent twice-weekly use plus bloodwork — not overnight after one half-tab. forum
If over-suppressed: Flat libido, dry eyes, dull affect, or “emotionally muted” reports appear in anecdotes when dosing continues without confirming high prolactin. Confounded by other cycle drugs. anecdote
Hours 0–3 (after a dose): Plasma peak often ~2–3 h. Nausea, lightheadedness, or a standing “head rush” can hit early — classic first-dose orthostatic window. trial
Days 1–3: GI unease, headache, dizziness, and fatigue are the usual early complaints; taking with food is commonly used to blunt nausea (food does not meaningfully change kinetics in volunteer PK). trial
Single-dose pharmacology lag: In hyperprolactinemic patients, maximal prolactin drop after a ~0.6 mg single dose was comparable to 2.5 mg bromocriptine but lasted much longer (~14 days vs ~24 h); time-to-max effect was slower for cabergoline (~48 h vs ~6 h for bromocriptine in that comparison). trial
Week 1–2: Some clinical and forum narratives note early sexual-symptom ticks if prolactin was truly high; many feel only sides at first. Steady-state accumulation for weekly dosing is expected after roughly ~4 weeks (half-life-driven). trial
~Week 4: Labeled titration and trial readouts often reassess serum prolactin around 4 weeks on a given dose before raising — weekly self-escalation without labs is a common community red flag. trial
Maintenance feel: Once prolactin is controlled clinically, dose is often stepped down; subjective “boost” fades into background while residual sides (orthostasis, GI, mood) may persist at higher cumulative exposure. trial

Cycles people discuss 7

AAS on-cycle pattern (community): Two camps — (1) start only if prolactin symptoms or labs appear on 19-nors; (2) prophylactic low-dose caber for the whole Deca/tren run. Symptom-only + labs is the more cautious forum consensus; blanket prophylaxis is debated. forum
Stop timing (AAS talk): Many discontinue after the 19-nor clears or sides resolve rather than running multi-month post-cycle caber without indication — still individual and unstandardized. forum
Titration pace: Labeled care spaces raises ≥4 weeks so prolactin response can be read; weekly jumps for “sex symptoms” without labs are repeatedly called higher-risk in community caution posts. forum
Labs people discuss: Serum prolactin (repeat after dose changes), and differential workup so E2-driven gyno/ED is not mislabeled as prolactin. Some also track testosterone/E2, CBC, and, for longer exposure, cardiac evaluation. forum
Re-challenge: Common on later 19-nor cycles if sides recur; cumulative cardiac/fibrosis risk remains the background long-horizon caution even if each run is short. forum
Clinical duration: Months to years under monitoring for prolactinoma/hyperprolactinemia — disease-driven, not a cut/bulk “cycle length.” Withdrawal is considered only after prolonged control (guidelines/discussions often cite ~2–3+ years of therapy with normal PRL and favorable imaging before a carefully supervised stop attempt). trial
Clinical withdrawal outcomes: After supervised long-term therapy, a substantial fraction recur (often within 12–18 months); some remain suppressed for years — highly diagnosis- and remnant-tumor-dependent. trial

Timing 11

Elimination half-life: Older notes cite ~63–69 hours in healthy volunteers and ~79–115 hours in hyperprolactinemia. The reviewed UK information gives 63–68 and 79–115 hours using different assays; these estimates are not a guarantee of multi-day symptom coverage. trial
Steady state: On the basis of half-life, steady-state conditions are expected after ~4 weeks of a stable weekly schedule; once-weekly repeat-dose data suggest steady-state levels ~2–3× a single dose. trial
Tmax / peak plasma: Mean peak ~2–3 hours after oral 0.5–1.5 mg in healthy volunteers; mean peaks often cited ~30–70 pg/mL in that range. trial
Dose proportionality: Plasma levels appeared roughly dose-proportional over ~0.5–7 mg single-dose exploration in volunteers/Parkinsonian patients. trial
Bioavailability: Absolute oral bioavailability unknown; significant first-pass effect. Protein binding ~40–42%. CYP450 contribution to metabolism described as minimal (hydrolysis of acylurea/urea moiety dominates). trial
Pituitary residence: Animal total-radioactivity work: pituitary radioactivity >100-fold vs plasma and eliminated with ~60 h half-life — consistent with prolonged prolactin suppression after plasma peak. animal
Duration of prolactin effect: Single oral doses can suppress prolactin for many days; hyperprolactinemia comparisons cite ~14-day effect vs ~24 h for bromocriptine after comparable single doses; some puerperal/single-dose follow-ups still show effect out to ~21 days. trial
Onset of measurable PRL drop: Volunteer and patient PD: inhibition can appear within hours (often cited from ~3 h); complete suppression more likely at ≥0.5–1 mg single doses. trial
After stop: Parent drug clears over days-to-weeks of washout given long half-life, but clinical hyperprolactinemia often returns on a months-scale if the underlying driver remains — track labs rather than assuming permanent “reset.” trial
CNS downstream: Orthostatic BP drop, dizziness, sleepiness/insomnia, impulse-control pathway stimulation (gambling, hypersexuality, compulsive shopping), and mood noise are class-consistent dopaminergic effects. trial
Pregnancy-planning clinical note: UK product information advises stopping one month before intended conception after regular cycles return. Specialist practice and individual circumstances are separate; this label statement is not a universal self-directed stop schedule. trial

Stacks 11

19-nor AAS adjacency: Most-discussed pairing is with nandrolone (Deca/NPP) or trenbolone when users attribute lactation-type sides, sexual dysfunction, or “prolactin gyno” to those compounds. Caber is treated as a side-management tool, not an anabolic. forum
Not an AI substitute: Estrogen control (anastrozole, exemestane, etc.) is a separate axis problem from prolactin. Forums repeatedly warn against using caber to “fix gyno” that is actually high-E2. forum
AI + caber (symptom-driven only): Some cycle logs run an AI for E2 and caber only if prolactin labs/symptoms also fire — dual blind self-medication without labs is a common failure mode. forum
Vs / with pramipexole: Compared for prolactin and libido talk. Caber: long-acting, usually 1–2×/week, ergot/valve narrative. Prami: non-ergot, typically daily microgram schedules, more sleepiness/impulse-control mental sides for some. Not interchangeable by anecdote alone. forum
P5P / vitamin B6 adjacency: Forums and some small clinical comparisons discuss pyridoxal-5-phosphate or higher-dose B6 as a milder prolactin-support alternative or adjunct; evidence is thinner and not equivalent to labeled cabergoline potency. forum
PDE5 combo: Occasional logs stack tadalafil/sildenafil for erection quality while using caber for presumed prolactin — separate mechanisms; hard to attribute which agent helped. anecdote
PT-141 / other libido agents: Mentioned in sexual-function stacks; dopaminergic + melanocortin combinations are experimental in user logs, not standard endocrine care. anecdote
TRT + low-dose nandrolone clinics: Some men’s-health threads discuss caber if prolactin rises on TRT±nandrolone joint-pain protocols — still lab-guided when done carefully. forum
Vs bromocriptine: Older multi-daily D2 agonist; generally less effective and less tolerated for hyperprolactinemia in head-to-heads — caber usually preferred when available. trial
Avoid dopamine-antagonist cancel: Antipsychotics and other D2 blockers can oppose cabergoline’s mechanism — clinical interaction theme. trial
BP-lowering drugs: Orthostatic risk rises when combined with antihypertensives or other hypotensive agents — label warning territory. trial

Storage notes 2

No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Related 8

Watch for 14

Over-suppression (forum theme): Libido crash, anhedonia, emotional flattening, or dry mucous membranes when dosing without confirmed high prolactin — a major reason communities push bloodwork before “just take caber with tren.” forum
19-nor prolactin debate: Some forum and animal-adjacent discussions argue nandrolone/tren do not reliably raise prolactin the way bro-science claims (estrogen/progestin/other factors may explain sides). Blind caber for every Deca cycle can be treating the wrong mechanism. forum
Drug interactions: Dopamine antagonists can oppose its prolactin effect; the UK label warns about macrolides increasing bioavailability and other medicines lowering blood pressure. Older azole/CYP3A4-inhibitor talk is not established as one class-wide mechanism by that label. trialforum
Source / legality / sport: Prescription drug in most places; WADA/sport status for ergot dopamine agonists should be checked by tested athletes; gray-market purity is untrusted. forum
Common trial/label AEs: Nausea, vomiting, headache, dizziness, constipation, abdominal pain, dyspepsia, fatigue/somnolence, and hot flashes are frequently listed. trial
Orthostatic hypotension: Standing BP drop, lightheadedness, syncope risk — especially early treatment or after dose hikes; initial single doses ≥1 mg raise orthostatic concern in product monographs. Greater risk with concurrent BP-lowering drugs. Rise slowly from sitting/lying. trial
Cardiac valvulopathy: Ergot D2 agonists with 5-HT2B activity (cabergoline, pergolide class) linked to valvular regurgitation, especially at high cumulative Parkinson’s-range doses. Prolactinoma-dose literature is more mixed (many series find no clear excess moderate-severe regurgitation at low weekly doses) but labels still require cardiovascular evaluation / consider echocardiography before start; contraindicated if valvular disease is present. Cumulative-dose monitoring talk continues for long-term users. trial
Pleural / pulmonary / retroperitoneal fibrosis: Class caution for long-term ergot agonists; history of these fibrotic disorders is a contraindication. New respiratory symptoms, edema, or unexplained abdominal/back pain need medical evaluation. trial
Impulse-control disorders: Pathological gambling, hypersexuality, compulsive shopping/eating, and related ICDs are recognized dopamine-agonist class effects — dose-related in safety communications; can reverse with dose cut or stop but are life-disrupting. trial
Psychiatric / mood: Depression, anxiety, and exacerbation of psychosis have been described; psychiatric history is a screening theme. trial
Contraindications (label core): Uncontrolled hypertension; history of cardiac valvulopathy; history of pulmonary, pericardial, or retroperitoneal fibrotic disorders; hypersensitivity to cabergoline or other ergot alkaloids. trial
Hepatic impairment: Severe hepatic insufficiency can increase exposure (AUC); caution / specialist dosing. trial
Pregnancy / lactation: Clinical use around fertility and pregnancy is specialist-managed (often stop when pregnancy confirmed after cycle restoration). Unsupervised use in pregnancy or while nursing is high-stakes; some regions use short regimens specifically to suppress lactation — different goal, still medical. trial
Parkinson’s high-dose context: Historical high mg/day Parkinson’s use is the main source of valvular-risk signal; do not import those doses into prolactin or AAS talk. trial

Updated: 2026-08-12

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Felt duration people report

What people say 10

Doses people talk about 17

How it may feel 8

Cycles people discuss 7

Timing 11

More on what it is 6

Stacks 11

Storage notes 2

Related 8

Watch for 14

Timing context & sources